As of 2026-05-31, the EV/EBITDA ratio of Fulgent Genetics Inc (FLGT) is -6.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FLGT's latest enterprise value is 518.50 mil USD. FLGT's TTM EBITDA according to its financial statements is -81.62 mil USD. Dividing these 2 quantities gives us the above FLGT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.4x - 12.5x | 10.6x |
| Forward P/E multiples | 8.8x - 11.3x | 9.6x |
| Fair Price | (25.08) - (30.35) | (27.07) |
| Upside | -238.3% - -267.3% | -249.2% |
| Date | EV/EBITDA |
| 2026-05-29 | -6.35 |
| 2026-05-28 | -6.39 |
| 2026-05-27 | -6.26 |
| 2026-05-26 | -6.18 |
| 2026-05-22 | -5.98 |
| 2026-05-21 | -6.08 |
| 2026-05-20 | -5.72 |
| 2026-05-19 | -5.55 |
| 2026-05-18 | -5.52 |
| 2026-05-15 | -5.46 |
| 2026-05-14 | -5.64 |
| 2026-05-13 | -5.56 |
| 2026-05-12 | -5.50 |
| 2026-05-11 | -5.51 |
| 2026-05-08 | -5.56 |
| 2026-05-07 | -5.25 |
| 2026-05-06 | -5.18 |
| 2026-05-05 | -5.17 |
| 2026-05-04 | -5.25 |
| 2026-05-01 | -4.89 |
| 2026-04-30 | -5.28 |
| 2026-04-29 | -5.13 |
| 2026-04-28 | -5.32 |
| 2026-04-27 | -5.43 |
| 2026-04-24 | -5.69 |
| 2026-04-23 | -5.58 |
| 2026-04-22 | -5.68 |
| 2026-04-21 | -5.55 |
| 2026-04-20 | -5.64 |
| 2026-04-17 | -5.67 |
| 2026-04-16 | -5.62 |
| 2026-04-15 | -5.63 |
| 2026-04-14 | -5.58 |
| 2026-04-13 | -5.32 |
| 2026-04-10 | -5.00 |
| 2026-04-09 | -5.22 |
| 2026-04-08 | -5.51 |
| 2026-04-07 | -5.54 |
| 2026-04-06 | -5.73 |
| 2026-04-02 | -5.87 |
| 2026-04-01 | -5.73 |
| 2026-03-31 | -5.54 |
| 2026-03-30 | -5.44 |
| 2026-03-27 | -5.42 |
| 2026-03-26 | -5.71 |
| 2026-03-25 | -5.82 |
| 2026-03-24 | -5.70 |
| 2026-03-23 | -5.69 |
| 2026-03-20 | -5.39 |
| 2026-03-19 | -5.41 |